409 related articles for article (PubMed ID: 32768938)
1. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a.
Zhao J; Yang X; Wang C; Song S; Cao K; Wei T; Ji Q; Zheng W; Li J; Zhou X; Liu J
Biomed Pharmacother; 2020 Sep; 129():110436. PubMed ID: 32768938
[TBL] [Abstract][Full Text] [Related]
2. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Akbari H; Tabrizi R; Lankarani KB; Aria H; Vakili S; Asadian F; Noroozi S; Keshavarz P; Faramarz S
Life Sci; 2020 Oct; 258():118167. PubMed ID: 32735885
[TBL] [Abstract][Full Text] [Related]
3. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.
Xin S; Cheng X; Zhu B; Liao X; Yang F; Song L; Shi Y; Guan X; Su R; Wang J; Xing L; Xu X; Jin L; Liu Y; Zhou W; Zhang D; Liang L; Yu Y; Yu R
Biomed Pharmacother; 2020 Sep; 129():110500. PubMed ID: 32768975
[TBL] [Abstract][Full Text] [Related]
4. Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19.
Fu HY; Luo Y; Gao JP; Wang L; Li HJ; Li X; Xue L; Tang XQ; Li HW; Du YR
Biomed Res Int; 2020; 2020():2854186. PubMed ID: 33015160
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].
Chen L; Liu HG; Liu W; Liu J; Liu K; Shang J; Deng Y; Wei S
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):203-208. PubMed ID: 32164089
[No Abstract] [Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19.
Schub D; Klemis V; Schneitler S; Mihm J; Lepper PM; Wilkens H; Bals R; Eichler H; Gärtner BC; Becker SL; Sester U; Sester M; Schmidt T
JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32937615
[TBL] [Abstract][Full Text] [Related]
8. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
[TBL] [Abstract][Full Text] [Related]
9. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
10. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between D-dimer concentration and inflammatory factors or organ function in patients with coronavirus disease 2019].
Xu Y; Qian Y; Gu Q; Tang J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 May; 32(5):559-563. PubMed ID: 32576347
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study.
Pan F; Yang L; Li Y; Liang B; Li L; Ye T; Li L; Liu D; Gui S; Hu Y; Zheng C
Int J Med Sci; 2020; 17(9):1281-1292. PubMed ID: 32547323
[No Abstract] [Full Text] [Related]
13. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
16. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic effect of Compound Qinlan Oral Liquid on treating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome].
Bao YY; Shi YJ; Guo SS; Geng ZH; Bao L; Sun J; Zhao RH; Gao YJ; Fang TH; Meng J; Cui XL
Zhongguo Zhong Yao Za Zhi; 2020 Apr; 45(7):1473-1480. PubMed ID: 32489023
[TBL] [Abstract][Full Text] [Related]
18. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.
Guo H; Zheng J; Huang G; Xiang Y; Lang C; Li B; Huang D; Sun Q; Luo Y; Zhang Y; Huang L; Fang W; Zheng Y; Wan S
Ann Palliat Med; 2020 Sep; 9(5):3235-3248. PubMed ID: 32954754
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-Lymphocyte Ratios Are Closely Associated With the Severity and Course of Non-mild COVID-19.
Qun S; Wang Y; Chen J; Huang X; Guo H; Lu Z; Wang J; Zheng C; Ma Y; Zhu Y; Xia D; Wang Y; He H; Wang Y; Fei M; Yin Y; Zheng M; Xu Y; Ge W; Hu F; Zhou J
Front Immunol; 2020; 11():2160. PubMed ID: 32983180
[TBL] [Abstract][Full Text] [Related]
20. Persistent lymphocyte reduction and interleukin-6 levels are independently associated with death in patients with COVID-19.
Xu Y; Wang N; Shen X; Liu X; Liu H; Liu Y
Clin Exp Med; 2023 Nov; 23(7):3719-3728. PubMed ID: 37310657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
